Skip to Content
You are currently on the new version of our website. Access the old version .
CancersCancers
  • Feature Paper
  • Article
  • Open Access

22 August 2025

17 Pages

Dinutuximab Beta Versus Naxitamab in the Treatment of Relapsed/Refractory Neuroblastoma in Patients with Stable Disease, Minor Response or Partial Response and Disease in Bone or Bone Marrow: Systematic Review and Matching-Adjusted Indirect Comparison

,
,
,
,
,
,
,
,
…
1
Department of Pediatric Hematology and Oncology, University Medicine Greifswald, 17489 Greifswald, Germany
2
Department of Nutrition and Drug Research, Institute of Public Health, Faculty of Health Sciences, Jagiellonian University Medical College, 31-008 Krakow, Poland
3
Paediatric Haematology Oncology, Jagiellonian University Medical College, 31-008 Krakow, Poland
4
Children and Adolescent Oncology Department, Gustave Roussy, Paris-Sud University, 94805 Paris, France

Simple Summary

No studies directly comparing dinutuximab beta (DB) and naxitamab (NAXI) in the maintenance treatment of relapsed/refractory neuroblastoma were identified in a systematic literature review. An indirect comparison was conducted based on the results of independent studies of DB and NAXI. Individual patient data from DB studies were adjusted to ensure that the characteristics of the patients were similar in the groups treated with the two antibodies. The study demonstrated that DB resulted in a longer survival period without the deterioration of neuroblastoma (referred to as progression-free survival) in comparison to NAXI (p = 0.015). In addition, a higher proportion of patients exhibited a positive response to DB in comparison to NAXI therapy (p = 0.044).

Abstract

Objective: Dinutuximab beta (DB) and naxitamab (NAXI) with GM-CSF are used for maintenance treatment of relapsed/refractory neuroblastoma. The objective of this study was to systematically assess comparative efficacy of the two therapies within their designated indications in accordance with established clinical guidelines. Methods: Relevant evidence was identified in systematic literature review. Individual patient data (IPD) from prospective clinical trials of DB were assessed and data on patients with disease in bone or bone marrow, as assessed in MRI, CT, mIBG or biopsy, with incomplete response to previous therapy were included. Patients with complete response, progressive disease and/or soft tissue disease were excluded. DB population was adjusted for sex, MYCN amplification, disease type (relapsed, refractory), and disease site (bone marrow and/or bone) to balance aggregated characteristics of NAXI population. More characteristics were included in sensitivity analyses, including DB treatment without interleukin-2, as currently recommended. Overall response rate (ORR) was assessed as best response. Results: Aggregated data for NAXI from Study 201 (n = 52) and Study 230 (n = 38) and IPD from DB studies (APN311-202, APN311-304, c = 77) met the inclusion criteria. Compared to NAXI, DB significantly extended progression-free survival (PFS): hazard ratio, DB vs. NAXI of 0.47 (95% CI: 0.26 to 0.87, p = 0.015). ORR was 60.1% (95% CI: 48.5% to 71.6%) for DB vs. 43.3% (33.1% to 53.6%) for NAXI (ORR odds ratio, DB vs. NAXI was 1.97, 95% CI: 1.02 to 3.80, p = 0.044). Sensitivity analyses and unadjusted comparisons supported the results. Conclusion: In the indirect comparison, dinutuximab beta significantly extended PFS and increased ORR compared to naxitamab.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.